サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1668408

メチシリン耐性黄色ブドウ球菌（MRSA）薬の世界市場レポート 2025年

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
メチシリン耐性黄色ブドウ球菌（MRSA）薬の世界市場レポート 2025年
出版日: 2025年02月28日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

メチシリン耐性黄色ブドウ球菌（MRSA）薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.8％で30億9,000万米ドルに成長します。予測期間の成長は、抗生物質耐性の継続的課題、MRSA診断の進歩、世界のヘルスケア関連感染、手術における予防対策、市中感染MRSA症例の増加などに起因しています。予測期間中の世界の動向としては、免疫調節剤の探索、薬剤開発のための戦略的パートナーシップ、菌株の特徴に基づくカスタマイズ治療、小児特異的製剤への注力、抗生物質耐性と闘うための世界保健イニシアティブなどが挙げられます。

院内感染（HAI）の増加が今後のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場の成長を牽引すると予想されます。HAIは、患者がヘルスケア施設で治療を受けている間に発症する感染症で、入院後48時間以上経過してから発症します。これらの感染症は、汚染された医療器具、ヘルスケアスタッフの手指衛生の不備、抗生物質の過剰使用、入院期間の長期化、患者の免疫力の低下など、さまざまな要因に起因しています。MRSA治療薬は、標準的な抗生物質に耐性を持つMRSA株を標的として排除することで、医療現場における感染症の蔓延と重症化を抑制し、これらの感染症を治療する上で極めて重要です。例えば、スイスに本部を置く政府間機関である世界保健機関（WHO）は2023年、世界全体で毎年推定1億3,600万件の医療関連抗生物質耐性感染症が発生していると報告しています。このように、MRSA感染の有病率の増加がMRSA治療薬市場の成長を促進しています。

高齢化はMRSA治療薬市場の拡大に寄与すると予想されます。65歳以上の高齢者と定義される高齢者層は、加齢に伴う免疫システムの低下により、MRSAを含む感染症にかかりやすくなります。高齢になると、感染症から体を守る免疫システムの働きが低下するため、MRSAのような細菌感染症が流行しやすくなります。世界保健機関（WHO）の2022年10月の報告書によると、2030年までに世界の6人に1人が60歳以上になると予測されています。60歳以上の人口比率は2020年の10億人から14億人に増加し、2050年には21億人に達します。その結果、高齢者のMRSA感染の増加がMRSA治療薬市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場：成長率分析
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場の実績：規模と成長, 2019-2024
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場の予測：規模と成長, 2024-2029, 2034F
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • リポペプチド
  • オキサゾリジノン
  • セファロスポリン
  • テトラサイクリン
  • 葉酸拮抗薬
  • リポグリコペプチド
  • その他の薬剤クラス
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 皮膚感染症
  • 骨と関節の感染症
  • 菌血症
  • 動物の感染症
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場：MRSAタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 院内感染（HA-MRSA）
  • 市中感染（CA-MRSA）
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 経口投与
  • 非経口投与
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院と診療所
  • 調査・学術機関
  • その他のエンドユーザー
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場、タイプ別サブセグメンテーション：リポペプチド、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ダプトマイシン
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場、タイプ別サブセグメンテーション：オキサゾリジノン、実績と予測, 2019-2024, 2024-2029F, 2034F
  • リネゾリド
  • テジゾリド
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場、タイプ別サブセグメンテーション：セファロスポリン、実績と予測, 2019-2024, 2024-2029F, 2034F
  • セフタロリン
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場、タイプ別サブセグメンテーション：テトラサイクリン、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ミノサイクリン
  • ドキシサイクリン
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場、タイプ別サブセグメンテーション：葉酸拮抗薬、実績と予測, 2019-2024, 2024-2029F, 2034F
  • トリメトプリムまたはスルファメトキサゾール
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場、タイプ別サブセグメンテーション：リポグリコペプチド、実績と予測, 2019-2024, 2024-2029F, 2034F
  • テラヴァンシン
  • ダルババンシン
  • オリタヴァンシン
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場、タイプ別サブセグメンテーション：その他の薬剤クラス、実績と予測, 2019-2024, 2024-2029F, 2034F
  • バンコマイシン
  • クリンダマイシン
  • キヌプリスチンまたはダルホプリスチン

第7章 地域別・国別分析

  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • メチシリン耐性黄色ブドウ球菌（MRSA）薬市場：競合情勢
  • メチシリン耐性黄色ブドウ球菌（MRSA）薬市場：企業プロファイル
    • Basilea Pharmaceutica Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Theravance Biopharma Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Allergan plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Cumberland Pharmaceuticals Inc.
  • Debiopharm International S.A.
  • AbbVie Inc.
  • Innovation Pharmaceuticals Inc.
  • Melinta Therapeutics Inc.
  • Nabriva Therapeutics plc
  • Paratek Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AmpliPhi Biosciences Corporation
  • AstraZeneca plc
  • Meiji Seika Kaisha Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Sanofi S.A.
  • Novartis

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • メチシリン耐性黄色ブドウ球菌（MRSA）薬市場2029：新たな機会を提供する国
  • メチシリン耐性黄色ブドウ球菌（MRSA）薬市場2029：新たな機会を提供するセグメント
  • メチシリン耐性黄色ブドウ球菌（MRSA）薬市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r24317

Methicillin-resistant Staphylococcus aureus (MRSA) drugs encompass a group of medications designed to treat infections caused by the bacterium Staphylococcus aureus that are resistant to methicillin and other commonly used antibiotics. These drugs are specifically selected to target and eliminate MRSA bacteria or hinder their growth. MRSA is a strain of staph bacteria that poses a challenge for treatment due to its resistance to antibiotics.

The main types of methicillin-resistant Staphylococcus aureus (MRSA) drugs include lipopeptides, oxazolidinones, cephalosporins, tetracyclines, folate antagonists, lipoglycopeptides, and others. Lipopeptides are a class of antibiotics containing both lipid and peptide components, and they act by disrupting the bacterial cell membrane, leading to membrane depolarization and inhibition of cell wall synthesis. These drugs find applications in treating various indications such as skin infections, bone and joint infections, bacteremia, and infections in animals. Methicillin-resistant Staphylococcus aureus (MRSA) is categorized into hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA) types. The administration of these drugs can be through oral or parenteral routes and is utilized by various end users, including hospitals, clinics, research and academic institutes, among others.

The methicillin-resistant staphylococcus aureus drugs market research report is one of a series of new reports from The Business Research Company that provides methicillin-resistant staphylococcus aureus drugs market statistics, including methicillin-resistant staphylococcus aureus drugs industry global market size, regional shares, competitors with a methicillin-resistant staphylococcus aureus drugs market share, detailed methicillin-resistant staphylococcus aureus drugs market segments, market trends and opportunities, and any further data you may need to thrive in the methicillin-resistant staphylococcus aureus drugs industry. This methicillin-resistant staphylococcus aureus drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The methicillin-resistant staphylococcus aureus (MRSA) drugs market size has grown steadily in recent years. It will grow from$2.35 billion in 2024 to $2.47 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to antibiotic resistance concerns, hospital-acquired infections, surgical procedures, global increase in MRSA cases, high mortality rates

The methicillin-resistant staphylococcus aureus (MRSA) drugs market size is expected to see strong growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to continued antibiotic resistance challenges, advancements in MRSA diagnostics, global healthcare-associated infections, preventive measures in surgery, rising community-acquired MRSA cases. Major trends in the forecast period include exploration of immunomodulators, strategic partnerships for drug development, customized therapies based on strain characteristics, focus on pediatric-specific formulations, global health initiatives to combat antibiotic resistance.

The rise in Hospital Acquired Infections (HAIs) is expected to drive the growth of the methicillin-resistant Staphylococcus aureus (MRSA) drugs market in the future. HAIs are infections that patients develop while receiving treatment in healthcare facilities, occurring 48 hours or more after admission. These infections are attributed to various factors, including contaminated medical equipment, poor hand hygiene among healthcare staff, overuse of antibiotics, prolonged hospital stays, and patients' weakened immune systems. MRSA drugs are crucial for treating these infections by targeting and eliminating MRSA strains that are resistant to standard antibiotics, thereby reducing the spread and severity of infections in healthcare settings. For example, in 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that an estimated 136 million cases of healthcare-associated antibiotic-resistant infections occur globally each year. Thus, the increasing prevalence of MRSA infections is fueling the growth of the MRSA drug market.

The aging population is expected to contribute to the expansion of the MRSA drugs market. Defined as individuals aged 65 and older, the elderly population is more susceptible to infections, including MRSA, due to compromised immune systems associated with aging. As people age, their immune systems become less effective at defending the body against infections, making bacterial infections such as MRSA more prevalent. According to the World Health Organization's October 2022 report, it is projected that by 2030, one in six people globally will be aged 60 or older. The proportion of the population aged 60 and over will increase from 1 billion in 2020 to 1.4 billion, reaching 2.1 billion by 2050. Consequently, the rise in MRSA infections among the elderly is contributing to the growth of the MRSA drugs market.

Product innovation is a key trend gaining traction in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market. Major companies in this sector are focused on developing new products to enhance their market position and improve their competitive edge. For example, in March 2023, Endo, a US-based biopharmaceutical firm, introduced the first generic version of Pylera (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) capsules, providing a more affordable treatment option for patients with Helicobacter pylori infections. This launch aims to increase access to effective therapies for gastric ulcers while contributing to cost savings in healthcare, ensuring that more patients can receive the necessary treatment to effectively manage their conditions.

Major companies in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market are focusing on once-daily dosing regimens to improve patient adherence to treatment, simplify medication schedules, and enhance the overall effectiveness of therapies designed to combat MRSA infections. Once-daily dosing regimens involve taking or administering a drug just once per day. For instance, in August 2024, Sun Pharma, an India-based biotechnology company, launched Tedizolid Phosphate tablets (200 mg), which provide a convenient once-daily dosing option for patients with acute bacterial skin and skin structure infections, including those caused by MRSA. This approach supports better treatment adherence and improved patient outcomes.

In June 2023, Brii Biosciences, a China-based company, acquired the exclusive global rights for BRII-693 from Qpex Biopharma for an undisclosed amount. This acquisition aims to enhance Brii's portfolio of innovative therapeutics targeting infectious diseases, especially those caused by multidrug-resistant pathogens. It strengthens the company's position in the global biopharmaceutical market and expands its ability to address critical unmet medical needs. Qpex Biopharma, a US-based company, specializes in manufacturing drugs for Methicillin-resistant Staphylococcus aureus (MRSA).

Major companies operating in the methicillin-resistant staphylococcus aureus (MRSA) drugs market include Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AmpliPhi Biosciences Corporation, AstraZeneca plc, Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.

North America was the largest region in the global methicillin-resistant staphylococcus aureus drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The methicillin-resistant Staphylococcus aureus (MRSA) drug market consists of sales of vancomycin, daptomycin, linezolid, ceftaroline, tedizolid, and clindamycin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on methicillin-resistant staphylococcus aureus (mrsa) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for methicillin-resistant staphylococcus aureus (mrsa) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The methicillin-resistant staphylococcus aureus (mrsa) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Class: Lipopeptides; Oxazolidinones; Cephalosporin; Tetracycline; Folate Antagonist; Lipoglycopeptide; Other Drug Classes
  • 2) By Indication: Skin Infections; Bone and Joint Infections; Bacteremia; Animal Infections
  • 3) By MRSA Type: Hospital-Acquired (HA-MRSA); Community-Acquired (CA-MRSA)
  • 4) By Route of Administration: Oral Administration; Parenteral Administration
  • 5) By End User: Hospitals and Clinics; Research and Academic Institutes; Other End-Users
  • Subsegments:
  • 1) By Lipopeptides: Daptomycin
  • 2) By Oxazolidinones: Linezolid; Tedizolid
  • 3) By Cephalosporin: Ceftaroline
  • 4) By Tetracycline: Minocycline; Doxycycline
  • 5) By Folate Antagonist: Trimethoprim Or Sulfamethoxazole
  • 6) By Lipoglycopeptide: Telavancin; Dalbavancin; Oritavancin
  • 7) By Other Drug Classes: Vancomycin; Clindamycin; Quinupristin Or Dalfopristin
  • Companies Mentioned: Basilea Pharmaceutica Ltd.; Merck & Co Inc.; Pfizer Inc.; Theravance Biopharma Inc.; Allergan plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Characteristics

3. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trends And Strategies

4. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Growth Rate Analysis
  • 5.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Total Addressable Market (TAM)

6. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Segmentation

  • 6.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lipopeptides
  • Oxazolidinones
  • Cephalosporin
  • Tetracycline
  • Folate Antagonist
  • Lipoglycopeptide
  • Other Drug Classes
  • 6.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Skin Infections
  • Bone and Joint Infections
  • Bacteremia
  • Animal Infections
  • 6.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital-Acquired (HA-MRSA)
  • Community-Acquired (CA-MRSA)
  • 6.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Administration
  • Parenteral Administration
  • 6.5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals and Clinics
  • Research and Academic Institutes
  • Other End-Users
  • 6.6. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipopeptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Daptomycin
  • 6.7. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Oxazolidinones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Linezolid
  • Tedizolid
  • 6.8. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Cephalosporin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ceftaroline
  • 6.9. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Tetracycline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Minocycline
  • Doxycycline
  • 6.10. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Folate Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Trimethoprim Or Sulfamethoxazole
  • 6.11. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipoglycopeptide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Telavancin
  • Dalbavancin
  • Oritavancin
  • 6.12. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Vancomycin
  • Clindamycin
  • Quinupristin Or Dalfopristin

7. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Regional And Country Analysis

  • 7.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 8.1. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 9.1. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 9.2. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 10.1. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 11.1. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 11.2. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 12.1. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 13.1. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 14.1. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 14.2. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 15.1. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 15.2. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 16.1. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 17.1. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 18.1. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 19.1. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 20.1. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 21.1. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 21.2. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 22.1. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 23.1. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 23.2. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 24.1. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 24.2. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 25.1. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 25.2. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 26.1. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 26.2. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 27.1. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 28.1. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 28.2. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

  • 29.1. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
  • 29.2. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Landscape
  • 30.2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Company Profiles
    • 30.2.1. Basilea Pharmaceutica Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Theravance Biopharma Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Allergan plc Overview, Products and Services, Strategy and Financial Analysis

31. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Other Major And Innovative Companies

  • 31.1. Cumberland Pharmaceuticals Inc.
  • 31.2. Debiopharm International S.A.
  • 31.3. AbbVie Inc.
  • 31.4. Innovation Pharmaceuticals Inc.
  • 31.5. Melinta Therapeutics Inc.
  • 31.6. Nabriva Therapeutics plc
  • 31.7. Paratek Pharmaceuticals Inc.
  • 31.8. Teva Pharmaceutical Industries Ltd.
  • 31.9. AmpliPhi Biosciences Corporation
  • 31.10. AstraZeneca plc
  • 31.11. Meiji Seika Kaisha Ltd.
  • 31.12. GlaxoSmithKline plc
  • 31.13. Johnson & Johnson
  • 31.14. Sanofi S.A.
  • 31.15. Novartis

32. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

34. Recent Developments In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

35. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market High Potential Countries, Segments and Strategies

  • 35.1 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer